Skip to content

US · HLN · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Haleon plc (HLN) intrinsic value and stock valuation

$9.07as of 2026-11-21 · Mkt cap 43.82B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Haleon plc DCF and intrinsic value

InvestorsCraft values HLN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from HLN’s statements →

Haleon plc Graham Number

Graham Number: $5.48d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Weybridge KT13 0NY haleon.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$11B+2.2% 5y CAGRd
20192025
Net income
$1.63B+7.3% 5y CAGRd
20192025
Free cash flow
$1.97B+12.6% 5y CAGRd
20192025
Total equity
$16.5B-8.9% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$11B$11.2B$11.3B$10.9B$9.55B
Operating income$2.41B$2.21B$2B$1.83B$1.64B
Net income$1.63B$1.44B$1.05B$1.06B$1.39B
EPSd$361.9K$314.3K$226.5K$229.5K$301K
Operating cash flow$2.29B$2.3B$2.1B$2.06B$1.36B
Capital expenditure-$-314.94M-$-250M-$-336M-$-328M-$-298M
Free cash flow$1.97B$2.05B$1.76B$1.74B$1.06B
Total assets$32.6B$34.3B$34.1B$34.8B$34.5B
Total debt$8.59B$10.1B$9.46B$10.4B$991M
Net debt$7.27B$7.91B$8.41B$9.76B$577M
Total equity$16.5B$16.2B$16.7B$16.5B$26.5B
Cash and short-term investments$1.32B$2.25B$1.04B$684M$414M
Income statement
20252024202320222021
Revenue$11B$11.2B$11.3B$10.9B$9.55B
Cost of revenue$3.83B$4.29B$4.34B$4.28B$3.6B
Gross profit$6.99B$6.95B$6.96B$6.58B$5.95B
Research and development expenses$308.1M$298M$311M$300M$257M
Selling, general and administrative expenses$4.36B$4.33B$4.29B$4.04B$3.79B
Other expenses-$-243.33M$111M$366M$415M$262M
Operating expenses$4.43B$4.74B$4.97B$4.75B$4.31B
Cost and expenses$8.62B$9.03B$9.31B$9.03B$7.91B
Interest income$76.3M$55M$14M$69M$13M
Interest expense$332.6M$394M$414M$347.4M$16M
Depreciation and amortization$352.1M$196M$309M$287M$268M
Ebitda$2.88B$2.51B$2.35B$2.18B$2.21B
Operating income$2.41B$2.21B$2B$1.83B$1.64B
Total other income/expenses, net-$-260M-$-296M-$-368M-$-207M-$-2M
Income before tax$2.15B$1.91B$1.63B$1.62B$1.64B
Income tax expense$461.7M$435M$517M$499M$197M
Net income$1.63B$1.44B$1.05B$1.06B$1.39B
Weighted average shares outstanding$4.48B$4.57B$4.63B$4.62B$4.62B
Weighted average diluted shares outstanding$4.51B$4.59B$4.63B$4.62B$4.62B
Balance sheet
20252024202320222021
Cash and short-term investments$1.32B$2.25B$1.04B$684M$414M
Net receivables$2.12B$1.9B$1.35B$1.49B$3.83B
Inventory$1.02B$1.19B$1.41B$1.35B$951M
Total current assets$4.54B$5.72B$4.82B$4.06B$5.25B
Property, plant and equipment, net$1.99B$1.92B$1.9B$1.9B$1.66B
Goodwill and intangible assets$25.6B$26.2B$26.9B$28.4B$27.2B
Long-term investments$75.9M$82M$65M$44M$23M
Total non-current assets$28B$28.6B$29.2B$30.8B$29.2B
Total assets$32.6B$34.3B$34.1B$34.8B$34.5B
Accounts payable$3.72B$1.97B$1.86B$1.84B$1.58B
Short-term debt$882.5M$1.49B$656M$437M$904M
Deferred revenue$33.9M$0.00$0.00$23M$11M
Total current liabilities$4.92B$5.81B$4.64B$4.37B$4.24B
Long-term debt$7.75B$8.62B$8.8B$10B$88M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$281M
Total non-current liabilities$11.2B$12.3B$12.7B$14B$3.73B
Capital lease obligations$133M$123M$137M$161M$117M
Total liabilities$16.1B$18.1B$17.3B$18.4B$7.97B
Common stock$89.8M$91M$92M$92M$1M
Retained earnings$16.1B$27.3B$27.5B$26.7B$38B
Accumulated other comprehensive income (loss)$335.4M$761.5M-$-10.96B$1.2B-$-11.63B
Total equity$16.5B$16.2B$16.7B$16.5B$26.5B
Total investments$75.9M$137M$65M$44M$23M
Total debt$8.59B$10.1B$9.46B$10.4B$991M
Net debt$7.27B$7.91B$8.41B$9.76B$577M
Cash flow statement
20252024202320222021
Net income$1.63B$1.44B$1.3B$1.12B$1.39B
Depreciation and amortization$352.1M$324M$309M$287M$268M
Stock-based compensation$0.00$102M$88M$78M$59M
Change in working capital$250.4M$48M-$-107M$181M-$-152M
Accounts receivable-$-63.58M-$-312M$38M-$-85M$14M
Inventory$130.1M$216M-$-131M-$-292M-$-17M
Accounts payable$122.3M$0.00$112M$387M$41M
Net cash provided by operating activities$2.29B$2.3B$2.1B$2.06B$1.36B
Investments in property, plant and equipment-$-403.95M-$-250M-$-234M-$-328M-$-298M
Acquisitions, net-$-157.47M$0.00-$-71M$9.21B$112M
Net cash used for investing activities-$-567.29M$528M-$-134M-$-8.78B-$-33M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-639.67M-$-121M-$-38M$0.00$0.00
Dividends paid-$-598.59M-$-570M-$-388M-$-2.68B-$-1.15B
Net cash used for financing activities-$-2.55B-$-1.54B-$-1.57B$6.91B-$-1.24B
Net change in cash-$-769.66M$1.21B$383M$205M$82M
Cash at end of period$1.32B$2.21B$994M$611M$405M
Operating cash flow$2.29B$2.3B$2.1B$2.06B$1.36B
Capital expenditure-$-314.94M-$-250M-$-336M-$-328M-$-298M
Free cash flow$1.97B$2.05B$1.76B$1.74B$1.06B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Haleon plc

        Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.

        CEO
        Brian James McNamara
        Employees
        24.54K
        Beta
        0.24

        Explore

        Frequently asked questions

        What is the intrinsic value of Haleon plc (HLN)?

        Haleon plc (HLN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is HLN undervalued?

        HLN trades at a price of $9.07 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.